Tezepelumab (Tezspire) for Severe Asthma: A Complete Patient Guide

What Is Tezepelumab?

Tezepelumab is a fully human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that functions as a master upstream initiator of airway inflammation across multiple inflammatory pathways. TSLP is not itself a product of the immune cascade — it is released by the airway epithelium, the first tissue that encounters inhaled triggers. When released, TSLP activates dendritic cells, mast cells, innate lymphoid cells type 2 (ILC2s), and T-helper cells, setting in motion both type 2 (eosinophilic, allergic) and non-type-2 inflammatory programs.

Marketed as Tezspire and co-developed by AstraZeneca and Amgen, tezepelumab received FDA approval in December 2021 for add-on maintenance treatment of adults with severe asthma. It subsequently received expanded approval for adolescents aged 12 and older. Uniquely among FDA-approved asthma biologics, tezepelumab's approval is not restricted by an eosinophil count threshold, a FeNO cutoff, or an IgE level — it is approved for severe uncontrolled asthma regardless of phenotype.

This phenotype-agnostic approval is the defining clinical feature that distinguishes tezepelumab from all other currently approved asthma biologics and makes it particularly relevant for the significant subset of severe asthma patients who lack elevated type 2 biomarkers.

How TSLP Blockade Works

Understanding tezepelumab requires understanding TSLP's unique position in airway biology — upstream of the entire inflammatory cascade, at the interface between the external environment and the immune system.

TSLP: The Epithelial Alarm Signal

The airway epithelium is not merely a passive physical barrier. It functions as an active sensor of environmental stress, releasing alarm signals (called alarmins) in response to:

• Inhaled allergens (house dust mite, cockroach, pollen, mold)
• Air pollutants (ozone, particulate matter, diesel exhaust particles)
• Viral and bacterial respiratory infections
• Cigarette smoke and chemical irritants
• Cold dry air and rapid temperature changes
• Physical distortion of the epithelium during bronchoconstriction

TSLP is the primary alarmin cytokine released in this epithelial stress response. Alongside IL-25 and IL-33 (two other alarmins), TSLP initiates the immune response that follows epithelial barrier disruption. In asthmatic airways, TSLP expression is chronically elevated, reflecting persistent epithelial activation by ongoing trigger exposure.

What TSLP Activates Downstream

Once released, TSLP acts on multiple immune cell populations simultaneously:

• Dendritic cells: TSLP primes dendritic cells to drive Th2 polarization, expanding the population of cells that produce IL-4, IL-5, and IL-13 — the core type 2 cytokines underlying eosinophilic asthma
• Innate lymphoid cells type 2 (ILC2s): TSLP directly activates ILC2s to produce large quantities of IL-5 and IL-13 rapidly, without requiring antigen presentation — this explains why non-allergic patients (who lack specific IgE sensitization) can still develop significant type 2 airway inflammation
• Mast cells: TSLP activates mast cells and may potentiate IgE-dependent and IgE-independent mast cell degranulation, contributing to bronchoconstriction and mucus secretion
• Natural killer T cells and neutrophil-activating pathways: TSLP also engages non-type-2 inflammatory pathways, which is why TSLP blockade shows benefit even in patients whose asthma is driven primarily by neutrophilic or mixed inflammation

Why Acting Upstream Matters

Anti-IL-5 agents (mepolizumab, benralizumab) act downstream, after the eosinophil-producing signal has already been generated. Anti-IL-4/IL-13 agents (dupilumab) act one step earlier but still within the type 2 arm of the cascade. Both approaches are effective when the patient's inflammation is predominantly driven by those specific cytokines.

But in patients whose asthma is driven by multiple cytokine pathways simultaneously — type 2 plus neutrophilic elements, or non-type-2 inflammation without meaningful eosinophilia — downstream blockade of a single pathway leaves other inflammatory drivers unaddressed. TSLP blockade intercepts the common upstream trigger that activates all of these pathways, providing a broader coverage effect than any single downstream target can achieve.

In practice, this means tezepelumab reduces not only blood eosinophils (by approximately 70% from baseline) but also FeNO, IgE, IL-5, IL-13, and measures of type 2 and non-type-2 inflammation simultaneously. No other approved asthma biologic achieves this breadth of biomarker suppression from a single target.

Who Qualifies for Tezepelumab?

FDA-Approved Indication

Tezepelumab is approved as an add-on maintenance treatment for patients with:

• Age 12 years and older
• Severe asthma that is inadequately controlled on medium-to-high-dose ICS plus at least one additional controller medication (GINA Step 4–5)
• No biomarker restriction — the FDA label does not specify a minimum eosinophil count, FeNO level, or IgE level

This biomarker-unrestricted approval is unique among asthma biologics and directly reflects the clinical trial design: the NAVIGATOR trial enrolled patients across the full spectrum of blood eosinophil counts and demonstrated statistically significant exacerbation reduction in every prespecified subgroup, including patients with eosinophils below 150 cells/mcL.

Patients Who Are Particularly Suited to Tezepelumab

• Non-eosinophilic severe asthma: Blood eosinophils persistently below 150–300 cells/mcL despite no oral corticosteroid use — these patients do not qualify for anti-IL-5 agents and show limited benefit from dupilumab; tezepelumab is the primary biologic option
• Mixed inflammatory phenotype: Patients with variable eosinophil counts across different assessments, or evidence of both eosinophilic and neutrophilic airway inflammation
• Severe asthma without clear atopic drivers: No significant allergen sensitization on IgE panel; exercise-triggered, cold air-triggered, or occupational asthma as dominant pattern
• Inadequate response to prior biologic therapy: Patients who have tried an anti-IL-5 agent or dupilumab and achieved suboptimal control may warrant a switch to tezepelumab, particularly if biomarker re-assessment reveals a non-type-2 component
• High exacerbation burden with uncertain phenotype: Patients with frequent exacerbations requiring ED visits or hospitalizations where type 2 biomarkers are equivocal

Patients Better Served by Other Biologics

Patients with very high eosinophil counts (≥500 cells/mcL), dominant atopic comorbidities (atopic dermatitis, EoE), or who require CRSwNP treatment may achieve comparable asthma control with tezepelumab but may derive additional clinical benefit from an agent with specific approval for their comorbid condition. For example, dupilumab's approval across atopic dermatitis, CRSwNP, and EoE may make it the preferred option when those conditions are significant. Phenotype evaluation and shared decision-making with your physician determine the optimal choice. Always consult your physician before making treatment decisions.

Clinical Trial Evidence for Tezepelumab

The NAVIGATOR Trial (Phase 3 Pivotal)

NAVIGATOR was the pivotal Phase 3 trial for tezepelumab, published in the New England Journal of Medicine in 2021. It enrolled 1,061 patients with severe, uncontrolled asthma on medium-to-high-dose ICS plus at least one additional controller. Patients were randomized to tezepelumab 210 mg subcutaneous every four weeks or placebo for 52 weeks. Crucially, enrollment was not restricted by blood eosinophil count — patients with eosinophils as low as zero were included.

Primary outcome (annualized asthma exacerbation rate, overall population):

• Tezepelumab: 56% reduction in exacerbation rate vs. placebo (rate ratio 0.44, 95% CI 0.37–0.53, p<0.001)
• Exacerbations leading to ED visit or hospitalization reduced by 70%
• Pre-bronchodilator FEV₁ improved by 130 mL vs. placebo at week 52
• Asthma Control Questionnaire-6 (ACQ-6) score improved by 0.33 points vs. placebo (clinically meaningful threshold: 0.5 points)
• St. George Respiratory Questionnaire (SGRQ) improved by 6.02 points vs. placebo (minimum important difference: 4 points)

Results by Eosinophil Subgroup

The prespecified subgroup analysis by blood eosinophil count is the most clinically important feature of the NAVIGATOR dataset:

The reduction in the low-eosinophil subgroup (<150 cells/mcL) is the most clinically groundbreaking finding: tezepelumab is the only approved biologic to demonstrate a significant, trial-validated reduction in severe asthma exacerbations in patients who would not qualify for anti-IL-5 therapy and show limited response to dupilumab. This has fundamentally changed the biologic therapy algorithm for non-eosinophilic severe asthma.

Biomarker Changes in NAVIGATOR

Tezepelumab produced reductions across all measured type 2 biomarkers, reflecting its upstream mechanism:

• Blood eosinophils: reduced by approximately 70% from baseline
• FeNO: reduced by approximately 40%
• Total IgE: reduced by approximately 45%
• IL-5, IL-13: reduced significantly from baseline

These reductions are broader in scope than those seen with any single downstream biologic, consistent with tezepelumab's upstream mechanism suppressing multiple cytokine pathways simultaneously.

The SOURCE Trial (OCS-Sparing)

SOURCE was a Phase 3 trial evaluating tezepelumab's ability to reduce oral corticosteroid (OCS) dependence in patients with OCS-dependent severe asthma, running concurrently with NAVIGATOR. Published in NEJM Evidence (2022), SOURCE enrolled 150 OCS-dependent patients and attempted systematic OCS reduction over 48 weeks.

Key findings:

• Tezepelumab group: median OCS dose reduction of 75% from baseline
• 40% of tezepelumab patients eliminated OCS entirely vs. 28% on placebo
• Exacerbation rate reduced by 74% in the tezepelumab group

Note: SOURCE did not reach its primary endpoint of a statistically significant difference in the proportion of patients achieving ≥90% OCS reduction, due in part to an unexpectedly high response rate in the placebo arm. However, the directional results and the 74% exacerbation reduction were clinically meaningful and supported the overall benefit profile of tezepelumab in OCS-dependent patients.

Long-Term Extension: DESTINATION

The DESTINATION open-label extension enrolled NAVIGATOR completers for an additional 52 weeks of tezepelumab therapy (total up to 104 weeks). Results confirmed that the exacerbation rate reduction was durable over two years of continuous therapy, with no evidence of tachyphylaxis or emerging safety signals. FEV₁ gains were maintained. These data support tezepelumab as a long-term maintenance therapy.

The PASSAGE Trial (Oral Corticosteroid Reduction, Real-World)

PASSAGE was an open-label, single-arm trial evaluating tezepelumab in patients previously on OCS or high-dose biologics in a real-world-like design. It confirmed feasibility of OCS reduction and transitioning from prior biologic therapy to tezepelumab in patients with inadequate prior responses, supporting the clinical practice of biologic switching.

Dosing and Administration

Approved Dose

Tezepelumab is administered as a single fixed dose: 210 mg subcutaneous injection every four weeks, for patients aged 12 and older. There is no weight-based dosing, no loading dose, and no dose titration — a single dose for all eligible patients, simplifying prescribing and administration compared to some other biologics.

Administration

Tezepelumab is available as a pre-filled autoinjector (Tezspire autoinjector) and a pre-filled syringe. The autoinjector is designed for self-administration without reconstitution. Injection sites are the thigh, abdomen, or upper arm. As with all biologic therapies, the first injection is typically administered in a clinical setting with a 30-minute observation period for hypersensitivity monitoring; subsequent doses are generally self-administered at home.

Storage

Tezepelumab should be stored in the refrigerator (2–8 degrees C / 36–46 degrees F). Before injection, it may be left at room temperature for up to 30 minutes. It should not be frozen. In Florida's summer heat, patients should be counseled to transport the autoinjector in an insulated bag and never leave it in a vehicle.

Concomitant Medications

Tezepelumab is an add-on maintenance therapy and should be used alongside existing controller medications, not as a replacement. Physicians will typically continue ICS-based regimens unchanged for the first 3–6 months while assessing biologic response, then consider stepdown of controllers or OCS if significant clinical improvement is documented.

Side Effects and Safety Profile

Tezepelumab has a favorable safety profile, consistent across the NAVIGATOR, SOURCE, and DESTINATION trials. It is generally well tolerated, with a side effect profile that compares favorably to other severe asthma biologics.

Common Side Effects

• Injection site reactions: mild pain, erythema, or swelling at the injection site, reported in approximately 4% of patients — lower than the injection site reaction rate reported for several other asthma biologics
• Pharyngitis (upper throat irritation): approximately 4%, comparable to placebo
• Arthralgia (joint pain): approximately 4%
• Back pain: approximately 4%

Notably, tezepelumab does not carry the conjunctivitis signal seen with dupilumab, nor the herpes zoster signal reported with mepolizumab. The side effect profile is notably clean for a biologic acting on a broad upstream target.

Hypersensitivity

Serious hypersensitivity reactions including anaphylaxis have been reported in the post-marketing setting. As with all injectable biologics, patients should be monitored after the first several injections and should seek emergency care if they experience urticaria, angioedema, respiratory distress, or hypotension following an injection.

Infections

No increase in serious infections, including upper respiratory tract infections or opportunistic infections, was identified in the NAVIGATOR or DESTINATION trial populations compared to placebo. Tezepelumab does not appear to meaningfully impair host defense against common respiratory pathogens, consistent with its targeted mechanism acting on an epithelial alarm signal rather than suppressing immune effector function broadly.

Parasitic Infections

TSLP plays a role in type 2 immune defense against parasitic infections. Theoretically, TSLP blockade could increase susceptibility to helminth infections, though no signal was identified in clinical trials. As with other type 2-targeting biologics, patients with ongoing parasitic infections should be treated before initiating tezepelumab, and patients traveling to helminth-endemic regions should discuss this with their physician.

Pregnancy and Lactation

There are limited human data on tezepelumab use during pregnancy. As a monoclonal IgG antibody, tezepelumab crosses the placenta in the second and third trimesters. A pregnancy exposure registry exists for patients exposed during pregnancy. Tezepelumab should be used during pregnancy only if the expected benefit outweighs the potential risk, as determined in consultation with your physician. The presence of tezepelumab in human breast milk is unknown. Always consult your physician regarding family planning and medication use during pregnancy or breastfeeding.

Immunogenicity

Anti-drug antibody (ADA) development was observed in approximately 3% of patients treated with tezepelumab in NAVIGATOR. The clinical impact was minimal; no consistent relationship between ADA positivity and reduced drug efficacy or altered safety was identified.

Tezepelumab for Non-Eosinophilic Asthma: A Critical Unmet Need

The availability of an effective biologic therapy for non-eosinophilic severe asthma represents one of the most significant advances in severe asthma management in recent years. Understanding why this population has been historically difficult to treat helps explain why tezepelumab's NAVIGATOR results were so impactful.

Who Has Non-Eosinophilic Severe Asthma?

Approximately 30–50% of patients with severe, uncontrolled asthma do not have persistently elevated blood eosinophil counts (<150–300 cells/mcL on multiple assessments, without oral corticosteroid use). These patients include:

• Patients with neutrophilic airway inflammation (often associated with obesity, smoking history, or bacterial airway colonization)
• Patients with paucigranulocytic asthma (normal eosinophil and neutrophil counts but persistent airway hyperresponsiveness)
• Patients whose type 2 inflammation is driven by ILC2 activation independent of Th2 cytokines (non-atopic eosinophilic asthma that is not captured by blood eosinophil counts)
• Patients with asthma triggered predominantly by environmental irritants, exercise, or occupational exposures rather than allergen sensitization

These patients have historically been left with no biologic option. The treatment algorithm — escalating doses of inhaled corticosteroids, adding long-acting bronchodilators, adding LAMA, considering low-dose oral corticosteroids — often reaches its limit without adequate control, leaving patients with ongoing exacerbations, ED visits, and hospitalizations.

Why Other Biologics Do Not Work in This Population

Anti-IL-5 agents (mepolizumab, benralizumab) specifically target eosinophilic inflammation. In patients without meaningful eosinophilia, there is no eosinophil-driven pathway to suppress, and clinical trials confirm these agents show little benefit in the low-eosinophil subgroup. Dupilumab has demonstrated some benefit even at lower eosinophil counts (via the FeNO pathway), but the effect size is attenuated in the fully non-type-2 population. Omalizumab requires confirmed IgE-mediated sensitization.

Tezepelumab's NAVIGATOR result — a 39% exacerbation reduction even in patients with eosinophils below 150 cells/mcL — was the first Phase 3 trial to show a significant benefit in this historically biologic-resistant group. For patients with non-eosinophilic severe asthma, tezepelumab is now the primary biologic option recommended in GINA 2025 guidance.

Considerations in South Florida

Non-eosinophilic asthma may be more prevalent in Broward County's patient population for several reasons. Obesity rates in South Florida are above the national average, and obesity is associated with a neutrophilic, non-eosinophilic asthma phenotype driven by adipokine-mediated systemic inflammation rather than type 2 cytokines. Occupational asthma from chemical irritants — common in construction, agriculture, cleaning services, and healthcare — often produces a non-eosinophilic or mixed inflammatory pattern. Patients with a long smoking or vaping history may have airway inflammation with a predominantly neutrophilic character. For these patient groups in particular, tezepelumab fills a therapeutic gap that previously did not exist.

Tezepelumab vs. Other Biologics for Severe Asthma

The comparison below is intended as an educational overview. The optimal biologic for any individual patient depends on phenotype, comorbidities, biomarker profile, and clinical history. Always consult your physician before making treatment decisions.

Tezepelumab vs. Mepolizumab and Benralizumab

In patients with high blood eosinophils (≥300 cells/mcL), all three agents demonstrate meaningful exacerbation reduction. The NAVIGATOR 70% reduction in the high-eosinophil subgroup is numerically comparable to anti-IL-5 trial results in similar populations. The choice between them in this subgroup often comes down to comorbidity profile, dosing frequency preference, and payer coverage. Mepolizumab's EGPA indication is unique; if EGPA is a concurrent diagnosis, mepolizumab is preferred. For patients without EGPA or CRSwNP, tezepelumab and anti-IL-5 agents are alternatives with similar efficacy in the eosinophilic group.

Tezepelumab vs. Dupilumab

In patients with elevated type 2 biomarkers and significant atopic comorbidities (atopic dermatitis, EoE, CRSwNP), dupilumab may be preferred because a single agent addresses multiple FDA-approved indications. Tezepelumab does not hold indications for these comorbidities. For patients with severe asthma as the primary concern, without major atopic comorbidities, and particularly where non-type-2 inflammatory components are suspected, tezepelumab is the stronger phenotype-agnostic choice. The every-four-week dosing of tezepelumab (vs. every two weeks for dupilumab) is also a practical advantage for patients managing frequent injection schedules.

Biologic Switching

Clinical guidelines support switching between biologics when an adequate trial (typically 3–6 months) of a first biologic produces suboptimal control. Patients who tried an anti-IL-5 agent without adequate response, particularly those who never clearly had high eosinophil counts at baseline, are reasonable candidates for tezepelumab. The PASSAGE trial data support the feasibility and safety of switching to tezepelumab from prior biologics.

What to Expect at Your First Visit

Phenotyping Evaluation

If you are referred for biologic evaluation or self-referring because your asthma remains uncontrolled on maximal inhaler therapy, Dr. Hull will conduct a full phenotyping assessment. This is especially important for patients being considered for tezepelumab, since its primary advantage is in patients who lack clear type 2 biomarker elevation — a group that requires careful characterization to exclude other diagnoses and confirm severe asthma as the driving condition.

The evaluation includes:

• Spirometry with reversibility — confirms airflow obstruction and bronchodilator response; near-normal spirometry does not exclude severe asthma but does prompt evaluation for alternative diagnoses including vocal cord dysfunction
• FeNO measurement — if low (<25 ppb) in a patient not on ICS, this supports a non-type-2 phenotype; if elevated, type 2 inflammation is present regardless of eosinophil count
• Blood eosinophil count — multiple assessments over time are more informative than a single value; oral corticosteroid use suppresses eosinophil counts and should be noted
• Total IgE and allergen-specific IgE panel — characterizes allergic contribution and omalizumab candidacy
• Induced sputum differential (where available) — direct airway cellularity assessment can identify neutrophilic or paucigranulocytic patterns that explain biologic non-response
• High-resolution CT chest (if not recently obtained) — to identify bronchiectasis, air trapping, or other structural contributors to symptoms

Ruling Out Mimics

In patients presenting with severe asthma and non-eosinophilic phenotype, it is important to systematically exclude conditions that can mimic asthma and may not respond to biologic therapy:

• Vocal cord dysfunction (VCD) / inducible laryngeal obstruction (ILO)
• Dysfunctional breathing patterns
• Hypersensitivity pneumonitis
• Bronchiectasis with airway hyperresponsiveness
• Cardiac causes of dyspnea (particularly in older patients)

Dr. Hull's evaluation is designed to identify these conditions before initiating expensive long-term biologic therapy on an incorrect diagnosis.

Prior Authorization and Access

Tezepelumab requires prior authorization. The list price is approximately $4,200–$4,800 per injection. Most commercial insurers cover tezepelumab for patients with documented severe uncontrolled asthma on appropriate step-up therapy; the biomarker-unrestricted label simplifies coverage arguments for patients with low eosinophil counts who previously could not meet anti-IL-5 eligibility criteria. The AstraZeneca/Amgen Tezspire patient support program (myTEZSPIRE) provides copay assistance for eligible commercially insured patients. Dr. Hull's office manages prior authorization submissions.

Response Assessment

Given tezepelumab's every-four-week dosing, response is assessed at approximately 12–16 weeks (3–4 injection cycles). Assessment includes exacerbation frequency, rescue inhaler use, spirometry, FeNO, and blood eosinophils. A decrease in FeNO and/or eosinophils confirms the drug is pharmacologically active. Clinical response — fewer exacerbations, less rescue inhaler use, improved quality of life — is the primary goal. If clinical response is adequate, therapy is continued long-term. Biomarker non-responders with good clinical outcomes are still considered treatment successes.

Severe Asthma Care in South Florida

South Florida's diverse patient population and year-round environmental exposures make phenotyping-guided biologic selection particularly important. Broward County's communities include large proportions of patients from Latin America and the Caribbean, populations with documented higher rates of asthma morbidity and emergency utilization. Occupational exposures in construction, agriculture, cleaning and hospitality services, and healthcare are common and may generate non-type-2 asthma patterns that are poorly served by eosinophil-targeted biologics.

The obesity prevalence in South Florida is significant, and obesity-associated asthma — characterized by neutrophilic or mixed-pattern airway inflammation, reduced response to ICS, and exacerbation patterns that differ from classic eosinophilic asthma — is a phenotype where tezepelumab may provide benefit that other biologics cannot.

At the same time, the year-round allergen burden (dust mites, cockroach, subtropical mold species, persistent grass and weed pollen) means that purely eosinophilic, allergic asthma is also highly prevalent. The clinical reality is that many South Florida patients with severe asthma present with mixed phenotypes — some type 2 features alongside non-type-2 components — where tezepelumab's upstream, phenotype-agnostic mechanism may deliver broader control than a narrowly targeted downstream agent.

Dr. Frank Hull, MD at Advanced Asthma Clinic in Plantation has 20+ years of experience managing difficult-to-treat and severe asthma across Broward County's diverse patient population. He has participated in multiple biologic therapy clinical trials and brings clinical trial rigor to biologic phenotyping and selection in his practice. Patients from Fort Lauderdale, Hollywood, Pompano Beach, Coral Springs, Miramar, Pembroke Pines, Deerfield Beach, Weston, Davie, and surrounding communities are seen at the Plantation clinic.

Frequently Asked Questions